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ABSTRACT
The reactions of [2+3] cycloaddition of pyridylnitrile oxides to vinyl- and allylgermanes
proceed regioselectively and afford 5-Ge-substituted isoxazolines-2. We have synthesized 9 new
pyridyl substituted 5-Si(Ge)-isoxazolines-2 and investigated their biological activity. The
vasodilating, anticoagulant and cardioprotective activities of 5-Si(Ge) substituted isoxazolines-2
have been studied in vitro and in vivo. Substitution of the silicon atom for the germanium one
leads to the significant increase in vasodilating, antithrombotic and cardioprotective activity. The
insertion of the methylene group between Ge and the isoxazoline ring reduces the vasodilating
activity. The most active isoxazoline- 3-(5"-triethylgermyl-3"-isoxazolinyl)pyridine hydrochloride
protects the heart from rhythm disturbances and lethality during ischaemia-reperfusion.
INTRODUCTION
In 1994 the first organogermanium pharmaceutical propagermanium was launched in
Japan under the trade name Serocion(R) (Sanwa Kenkyusho Co.,Ltd.). Its biological activity
spectrum includes the protection against viruses, imrnunostimulation and hepatoprotection.
Propagermanium has been introduced into clinics for the treatment of chronic hepatitis. This
compound belonging to germsesquioxanes has been shown to possess low toxity.
This achievement has stimulated the further investigations of the biological activity not
only of germsesquioxanes but also of other classes of low toxic organogermanium compounds.
Hetaryigermatranes show relatively high neurotropic activity [1, 2]. Triphenylgermyl
substituted 1,2,4-triazolinones were effective against gastric carcinoma MGC-803 under the
experimental conditions. However, no inhibitory effects were found against carcinoma BGC-823
[3].
[2+3] Cycloaddition reactions of nitrile oxides to vinylsilanes proceed regiospecifically to
give 5-Si substituted isoxazolines-2 [4-8], however, the addition to vinyltriethoxysilane and
vinylsilatrane gives a mixture of 4- and 5-Si regioisomers [9]. Silyl substituted isoxazolines show
wide spectrum of the biological activity [10].
The aim of the present work is the synthesis and investigation of vasodilating and
cardioprotective activity of pyridyl substituted silyl- and germylisoxazolines.
MATERIALS AND METHODS
Chemistry
H NMR spectra were recorded on a Bruker WM-360/DS instrument at 360.1 MHz. GLC analysis
was perfomed on a Varian 3700 instrument equipped with flame-ionizing detector using a capillar
column 5 m 0.53 ram, df=2.65 , HP-I. Carrier gas nitrogen.
The melting points were determined on a "’Digital melting point analyzer" (Fisher), the
results are given without correction.
Genera/method of preparation.
An equimolar amount of triethylamine in benzene (20 ml) was gradually added to a
solution of vinyl(allyl)triethylsilane(germane) (0.02 mol) and pyridylhydroxamic chloride (0.02 mol)
in benzene (30 ml) at 70 C. After addition of amine the mixture was stirred for 4 h at the same
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temperature. When the temperature of the reaction mixture fell to ambient, triethylamine
hydrochloride was filtered off. The solvent was evaporated in vacuo and the residue was
extracted with hexane. Hydrohalogenation was carried out by HHal in ether.
Table 1. Silyl(germyl)isoxazolines-2.
(,)
(2)
(3)
(4)
(6)
(7)
(s)
(9)
2-(5" -triethyls lyl-3"
isoxazolinyl)pyridine hydrobromide
3-(5" -triethyis lyl-3"
isoxazolinyl)pyridine hydrobromide
4-(5"-triethylsilyl-3"-
isoxazolinyl)pyridine hydrobromide
2-(5"-triethylgermyl-3"
isoxazolinyl)pyridine hydrochloride
3-(5" -triethylgermyl-3"
isoxazolinyl)pyridine hydrochloride
4-(5" -triethylgermyl-3"
isoxazolinyl)pyridine hydrochioride
2-(5"-triethylgermylmethyl-3"-
isoxazolinyl)pyridine hydrochloride
3-(5"-triethylgermylmethyl-3"
isoxazolinyl)pyridine hydrobromide
4-(5"-triethylgermylmethyl-3"
isoxazolinyl)pyridine hydrobromide
M.p.=198C (from ethyl acetate).
M.p.=168C (from ethyl acetate).
M.p.=181C (from acetone/ethanol (10:1)).
M.p.=115C (from ethyl acetate/ methanol
(2:1)).
M.p.=114C (from acetone/benzene (3:1)).
M.p.=148C (from acetone).
M.p.=102C (from ethyl acetate/ methanol
(4:1)).
M.p.=148C (from ethyl acetate/ 2-propanol
(1:1)).
M.p.=183C (from ethyl acetate).
Pharmacology
Vasodilating activity. The modified classical method for the experiments on the isolated perfused
rabbit ear blood vessels was used [11, 12]. Rabbits of both sexes (2.6-3.3 kg) were killed by L v.
injection of pentobarbital sodium (80 mg/kg). The central ear artery was dissected free at the
base of the ear and cannulated with polyethylene tubing and perfused at a constant flow
(2ml/min) from 4-channel peristaltic pump Geming (Italy).
The content of the perfusion fluid (mmol) was as follows: NaCI 136.9; KCI 2.68; CaCIz
1.8; MgCI 1.05; NaHCO 11.9; NaHPO 0.42; glucose 5.6 (pH 7.35 at 22C). Intraluminai inflow
perfusion pressure was measured with a Statham P23J transducer and recorded on a
physiograph DMP-4B (Narco Bio-Systems, USA). As flow remained constant, the changes in
perfusion pressure reflected changes in blood resistance, i.e. the degree of vasoconstriction or
relaxation. Vasoconstriction was caused by intraluminal infusion of noradrenaline (10 mol). The
investigated compounds were dissolved in perfusion fluid. The relaxant responses to the
investigated compounds used in the different concentrations (10 and 50 mol) were tested.
Responses are expressed as per cent relaxation (% changes in the perfusion pressure) without
and with the investigated compounds.
Thrombos formation time. Blood coagulation time was detected using Lee&White method
[13]. White male mice of ICR-JCL strain (20-22 g) were used in the experiments (5 mice in every
group). The studied compounds were administered i.p. 15 min prior the experiments. Blood was
sampled from jugular vein from the previously anaesthetized mice (urethane 900 mg/kg, i.p.). The
inhibition degree, the blood coagulation time for each compound in a dose of 30 mg/kg were
expressed in min and in % ratio in comparison with the control (the blood coagulation time in the
case of the solvent -0.6% solution of Tween 80).
Blood bleeding time. Blood bleeding time was measured following Duke [13]. White male
mice of ICR-JCL strain (20-22 g) were used in the experiments (5 mice in every group). The
studied compound or solvent (0.6% solution of Tween 80) was administered i.p. 15 min prior the
test. The blood bleeding was caused from tail of the anasthetized mice (urethane 900 mg/kg, i.p.).
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Table 2. Spectral and analytical data of compounds 1-9.
N Mol.Formula ield
(%)
1H-NMR spectra(360,i-MHz,CDCi/TMS,
303 K), 5(ppm);
Calc. (%)(fecund)
N
C
H
1 CI4HBrNOSi 52 0.76(6H, dq, J=’1.8 Hz, J=5.6"HZ}, i’.62(9HI t, 811’6(8 18)
J=5.6 Hz), 3.57 (1H, dd, J=10.2, J=21.9 Hz), 48.96(49.05)
4.29 (1H, dd, J=10.2, J=21.9 Hz), 4.52(1H, dd, 6.75(6.76)
J=10.2 Hz, J=21.9 Hz), 7.98(1H, dt, J=2.1 Hz,
J=5.6 Hz), 8.31-8.56 (2H, m), 9.00 (1H, dd,
J=.1.0 HZ, .J=..5...6..Hz)
2 C,4HBrNOSi 44 0.73 (6H, dq, J=1.8 Hz, J=5.8 Hz), 1.06(9H, t, 8’.16(8122)
J=5.8 Hz), 3.23(1H, dd, J=11.6 Hz, J= 15.6 48.96(49.07)
Hz), 3.69 (1H, dd, J=11.6 Hz, J=15.6 Hz), 6.75(6.83)
4.42(1H, dd, J=11.6 Hz, J=15.6 Hz), 8.04-8.17
(1 H, .m), 8.89-9.2 (3H,......m).
3 C,I21BrNOSi ,4 0.78 (6H, dq, j=2.1 Hz, J=6.2 HZ), ’1.05 (9H, {, 8.16(8.20)
J=6.2 Hz), 3.42 (1H, dd, J=11.8 Hz,J=16.2 Hz), 48.96(48.85)
3.83 (1H, dd, J=11.8 Hz, J=16.2Hz), 4.53 (1H, 6.75(6.81)
dd, J=11.8 Hz, J=16.2 Hz), 8.41 (2H, d, J=6.6
Hz), 9..05 (2H, d, J=6.6 Hz).
4 C,HCIGeNO 70 0.96 (6H, q,J-S.7i-lzi"; :i111"(9H, t, j=8".1 H)i 8.i5(8.13)
3.54(1H, dd, J=12.0 Hz, J=17.2 Hz); 4.34 (1H, 48.98(48.92)
dd, J=12.0 Hz, J=15.7 Hz); 4.65 (1H, dd, 6.75(6.78).
J=15.7 Hz, J=17.2 Hz); 7.87 (1H, t, J=6.3 Hz);
8.34 (1H, td, J=0.7 Hz, J=1.3 Hz, J=8.3 Hz);
8..5.0...(1H., d, J=8..1.Hz);..8.88 (1H, d, J=5.7 Hz).
5 C4HzCIGeNzO 47 0.98 (6H, m); 1.11 (9H, m); 3.21 (1H, dd, 8.15(8.15)
J=11.4 Hz, J=15.5 Hz); 3.65 (1H, dd, J=11.4 48.98(48.99)
Hz, J=15.5Hz), 4.45(1H, dd, J=11.4Hz, J=15.4 6.75(6.71).
Hz); 8.01 (1H, dd, J=7.4 Hz, J=11.4 Hz); 8.81
(1H, m); 8.91 (1H, d, J=5 Hz).
’6 C4HCIGeNO "45 0.:78-1.31 (l5H,m);’ 3’.20 (1H, dd, J=i1.1 Hz, 8.15(8,0t)
J=14.5 Hz); 3.64 (1H, dd, J=11.1Hz, J=14.5 48.98(48.81)
Hz); 4.64 (1H, dd, J=11.1 Hz, J=14.5 Hz); 8.16 6.75(6.72).
(2H, d, J=5.Z HZ).; 8.9 (2H, d, J=5.7 HZ),.
7’ C,HzCIGeNO 43 0.88(6H,qd,J=1.5 ’Hz,J=7.2" Hz);1.0(9H, "7.84(7.82)
t,J=7.4 Hz); 1,28 (1H, dd, J=7.8 Hz, J=13.5 50.41(50.41)
Hz); 1.41(1H, dd, J=7.8 Hz, J=13.5 Hz); 3.42 7.05(7.06).
(1H, dd, J=9.4 Hz,J=17.7 Hz); 4.07 (1H, dd,
J=10.5 Hz, J=17.7 Hz); 5.15 (1H,m); 7.83 (1H,
t, J=6.5Hz); 8.31 (,1H, m); 8.47 (1H, d, J=8.3
.Hz); .8.84.{1H,..d, J=5.0 Hz).
8 CHzBrGeNO "45 0.76-1.22(15H,m);1.S(2H,t,j=10"H);2"gF(1H’, 6197(6.98)
dd,J=10 Hz, J=17 Hz); 3.56 (1H, dd, J=10 Hz, 44.83(44.85)
J=17 Hz); 4.96-5.15 (1H, m); 8.0-8.15 (1H, m); 6.27(6.23).
8.91-9.10 (3H;..m)..
9 CsHBrGeNO 44 0.74-1.22 (15H, m); 1.35 (2H, t,J=8 Hz); 2.94 6.97(6.98)
(1H, dd,J=9 Hz, J=16 Hz);3.51(1H, dd, J=9 Hz, 44.83(44.85)
J=16Hz); 5.13 (1H, m); 8.17 (2H, d, J=6 Hz); 6.27(6.27).
8.98 (.2H.,...d..,.J=6 Hz)..
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Heart failure produced by the coronary artery occlusion and reperfusion. In acute trials on
the anaesthetized (pentobarbital sodium, 50 mg/kg, i.p.) male Wistar rats (310-330 g) with
artificial respiration (respirator V5kG Narco Bio-System, USA) the chest was open. A sling (6.0
silk Ethikon) was placed around the left coronary artery close to its origin and after recovery, the
coronary artery was occluded for 10 min and reperfused (30 min). Incidence and duration of
arrhythmia (ventricular tachycardia, fibrillation), ST-segment changes in ECG and mortality have
been evaluated. All data were registered on a physiograph DMP-4B (Narco Bio-System, USA).
The compounds were dissolved in 0.9% solution of NaCI and administered i.v. 5 min before the
occlussion of coronary artery. The cardioprotective activity of the investigated compounds was
compared with that of AIIopurinol (xanthine oxidase inhibitor) which improved cardiac function and
lowered hospital mortality rate in patients undergoing cardiac surgery [14].
Acute toxicity. The acute toxicity was evaluated in male ICR-JCL mice (19-23 g). The
compounds were dissolved-suspended in 0.6% solution of "l’ween 80 and injected i.p.. To reduce
the number of the used animals the maximal dose (400 mg/kg, i.p.) was used.
Statistical analysis. The results were presented as mean + SEM for each group. The
statistical analysis was perfomed using the Student’s test for the unpaired data and Chi-square
test. The results were considered as reliable at p<0.05.
RESULTS AND DISCUSSION
Chemistry
We have found that vinyltriethylgermane and allyltriethylgermane readily reacted with
nitrile oxides giving the corresponding 5-Ge-isoxazolines-2 in relatively good yields (42-73%):
Et3M(CH2)nCH=CH2 +
Et3M(CH2)n
M=Si, Ge; n=0, 1.
Hydroxamic chlorides were obtained by the method described in Refs 15 and 16, and
were transformed into cyanopyridine oxide [Py-C-=N/-O] in the presence of triethylamine. The
product formed interacted with vinyl(allyl)triethylgermane in the [2+3] cycloaddition reaction,
affording the derivatives of 3-pyridyl-5-germyl substituted isoxazolines.
H NMR data evidence that 5-triethylsilyl(germyl)-substituted isoxazoline is formed. The
signals of two protons (H, and H) in 4 position of isoxazoline ring appear in the spectrum of
compound 1: H, at 3.57(dd, J =10.2 Hz -interaction with H, 3J=21.9 Hz -interaction with Ho) and
H at 4.29(dd, J =10.2 Hz -interaction with H, J=21.9 Hz -interaction with H). Ho in 5 position
resonates in lower field as o-substitutent is oxygen atom: 4.52(dd, 3J =10.2 Hz, J=21.9 Hz).
H NMR data for compound 4 are similar H, 3.54(dd, J=12.0 Hz interaction with H,
3J=17.2 Hz interaction with H); H 4.34 (dd, J=12 Hz interaction with H, 3J=15.7 Hz
interaction with H); H 4.65(dd, 3J=15.7 Hz- interaction with H, 3J=17.2 Hz -interaction with
H NMR data for compound 7 differ to some extent due to the methylene group (H, H).
H: 1.28 (dd, J=7.8 Hz- interaction with H., 3J=13.5 Hz- interaction with H), H, 1.41 (dd, J=7.8
Hz -interaction with H, J=13.5 Hz- interaction with Ho). Protons H, and H resonate like in
compounds 1 and 4. H,: 3.42 (dd, J=9.4 Hz, J=17.7 Hz), H: 4.07 (dd, J=10.5 Hz, J=17.7 Hz). H
proton is shifted towards lower field (5.15, m).
Polarization of the vinyl group in triethylvinylgermane and triethylallylgermane is opposite
and, consequently, one can expect the different regioselectivity of the nitrile oxides addition, while
it has been proved experimentally that the addition occurs analogously [15-18].
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Table 4. Vasodilating activity of the investigated compounds in noradrenaline-preconstricted
rabbit’s ear artery.
Compound
Solvent
Concentration (1 moi)
10
5O
10
5O
10
5O
10
5O
10
5O
10
5O
Relaxation (%)
+ 8
_+15
23
34*
18
32*
16
32*
27*
36*
+ 0
12
_+ 0
Significantly differs from the control (solvent) (P<0.05).
Table 5. Anticoagulant activity and acute toxicity of the investigated compounds.
(i.p. administration to white mice)
Compound BIoodbleeding time Coagulation time
mln
1.65 +0.20
1.33 +__0.15
1.75 _+0.28
1.80 +0.18"
1.30 +0.14
1
2
3
4
5
6
7 113.3
8
Control 100
SignificantlY differs fromihe cont’:01 (P<0.05).
1.36 +0.14
1.20 +_0.25
(%)
137.5
110.8
145.8
150
108.3
min
2.88 _+0.30
2.85 +_0.33
3.00 +0.35
3.07 +0.30*
3.40 +0.34*
3.10 +0.32*
2.25 +0.25*
(%)
128
127
133
136
151
137
100
LDs0
(mglk.g)
447
515
325
410
355
355
708
515
Table 6. Effect of silyl(germyl) substituted isoxazolines and AIIopurinol on ischaemia reperfusion
induced rhythm disturbances and lethality of rats.
Compound
1
2
3
4
5
Ailopurinol
Control
(0.9% NaCI)
Dose
(mglkg, i.v.)
5.0
2.0
2.0
2.0
2.0
10.0
Rhythm Disturbances’’’
Ventricular Ventricular
tachycardia fibrillations
9/10 7/10
9/10 6/10
10/10 8/10
11/12 7/12
9/10 4/10"
8/10 6/10
15/15 14/15
Ratio-incidence/number of animals n experiment;
Significantly differs from the control (solvent) (P<0.05).
Lethality
3/10
1/10"
3/10
1/12"
0/10"
1/10"
7/15
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Pharmacology
In experiments on noradrenaline-preconstricted blood vessel of a rabbit’s ear we
investigated the vasodilating activity of the newly synthesized silyl and germyl isoxazolinyl
substituted pyridines. Compounds 2, 3, 4, and 5 induced significant vasodilatation (5 being the
most active). Compound 7 revealed weak vasodilation, but compound 1 induced 2-phase activity
vasodilatation/vasoconstriction (Table 4). Thus, we have found, that substitution of the silicon
atom for germanium leads to the increase of vasodilating activity (1,2-4, 5), but the insertion of
the methylene group between Ge and isoxazoline ring reduces vasodilating activity (compounds
4 and 7).
Table 5 summarizes the data on the anticoagulant activity of silyl(germyl)isoxazolines-2.
In the experiments on mice the investigated compounds in general have no significant influence
on the blood bleeding time (except compound 4 prolongation of the bleeding time against
control 150%).
It has been shown that all investigated germylisoxazolinyl substituted pyridines (4, 5 and
7) prolong the coagulation time (table 5), 3-(5"-triethylgermyl-3"-isoxazolinyl)pyridine
hydrochloride (5) being the most active anticoagulant among all studied compounds. In this
experiment silyl isoxazoline substituted pyridines (1-3) reveal weak anticoagulant activity.
In the experiments on the anasthetized rats 2, 4, 5 and AIIopurinol protected animals from
ischaemia reperfusion induced lethality (table 6). Under our experimental conditions (15 min
coronary artery occlusion with subsequent reperfusion) only the compound 5 protected heart from
ventricular fibrillation.
In the experiments in vitro and in vivo it has been found that substitution of the silicon
atom for the germanium one increases significantly the vasodilating and anticoagulant activity
and leads to rise of cardioprotective properties of 3-pyridyl substituted isoxazolines. The insertion
of the methylene group between Ge and the isoxazoline ring reduces the biological activity in the
studied compounds.
It must be noted that germylisoxazolines 4 and 7 are also more potent (by 15-30 times)
NO-inducers in HT-1080 (human lung fibrosarcoma) and MG-22A (mice hepatoma) cells than the
silicon derivatives 1 and 2.
This group of compounds has a medium toxicity. The most toxic compound among all
studied was 4-(5"-triethylsilyl-3"-isoxazolinyl)pyridine hydrobromide (325 mg/kg). The introduction
of the methylene group between the triethylgermyl group and isoxazoline ring decreased the
toxicity. 2-Pyridyl substituted isoxazolines are less toxic than 3- and 4-pyridyl substituted
analogues. Triethylsilylisoxazolines are more toxic than germyl analogues.
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